CytRx

CytRx is a biopharmaceutical research and development company specializing in oncology.

Business Model:

Revenue: $0

Employees: 1-10

Detailed CytRx Information

Geographic Data

CytRx headquarters map

Address:

City: Los Angeles

State: California

Zip:

Country: United States

Financial Info

Stage:

post ipo equity

Raised Last:

$10M

Raised Total:

$143M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

CytRx is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company is initiating a Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene.

Contact Phone:

Contact Email:

CytRx went public on 11/3/2017 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
11/3/2017

Ticker Symbol:
CYTR

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
2/2014 Post-IPO Equity $86M
2/2016 Post-IPO Debt 1 $40M Hercules Capital
Hercules Capital
5/2018 Post-IPO Equity $6.5M
7/2021 Post-IPO Equity $10M
Announced Date Name Price
9/2008 Innovive Pharmaceuticals
10/2004 Biorex Research and Development
2/2002 Global Genomics Capital

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research